Before 2006 gadolinium-based contrast media were considered to be safe and this led to very liberal use of these agents. They were even used for conventional X-ray and computed tomography (CT) in patients considered to be at increased risk of contrast-medium-induced nephropathy after administration of iodine-based contrast media. The link between gadolinium and the development of nephrogenic systemic fibrosis (NSF) shocked the radiological community. However, within 2 years of the first reports from Austria and Denmark (1,2) it was clear that NSF was only seen after intravenous administration of the less stable agents and only in patients with severely reduced renal function or on renal replacement therapy. Not all patients who got the least stable agents developed NSF, and some patients had only received a small amount of the contrast agent while others had had large amounts (3). Also, the majority of patients who had reduced renal function and received a gadoliniumbased contrast medium did not develop NSF. Fortunately, stopping the use of the less stable agents in patients with reduced renal function in large part stopped patients developing NSF. However, there are still patients who develop NSF many years after they had an injection of one of the less stable linear agents
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Just as we thought we were putting the problem of NSF behind us, a new adverse effect after gadoliniumbased contrast media was reported: a slow increase over time in the signal intensity of the dentate nucleus and the globus pallidus on unenhanced T1-weighted (T1W) images. The clinical significance of the increase in intensity is still not known. Unlike NSF, the overwhelming majority of reported cases had normal renal function at the time of administration.
Almost 20 years ago, high signal intensity in the basal ganglia was documented in patients with high levels of manganese in the blood (4). The patients developed Parkinsonism-like symptoms. Manganese-based contrast agents were not marketed then, so the high manganese levels came from other sources, such as parenteral nutrition, or high levels of manganese in the air at steel plants.
Hyperintensity on unenhanced T1-weighted images
In 2014 Kanda et al. (5) reported that high signal intensity in the dentate nucleus and globus pallidus on unenhanced T1W images could be a consequence of the number of previous administrations of gadoliniumbased contrast media, based on observations in 16 patients. The following year they reported that hyperintensity in the dentate nucleus is associated with previous administration of linear gadoliniumbased contrast media (gadodiamide and gadopentetate dimeglumine), but not with administration of macrocyclic agents (6) . Unlike the patients who developed NSF, the patients who developed hyperintensity of these brain structures had normal renal function. Ramalho et al. (7) found increased signal intensity in the dentate nucleus and globus pallidus after multiple gadodiamide injections (mean, 5.0 doses) in 23 patients but not after gadobenate dimeglumine (Multihance Õ ) enhanced examinations (mean, 4.6 doses) in 46 patients. However, the rate-of-change data indirectly suggest gadolinium deposition in the dentate nucleus after gadobenate, although it was considerably less than after gadodiamide. Radbruch et al. (8) looked at images from 100 patients who received either gadopentetate dimeglumine (50 patients) or gadoterate meglumine (50 patients) and who had at least six enhanced MR examinations. Again, hyperintensity developed only in those patients who had the linear chelate, gadopentetate dimeglumine. Around 80% of the patients had a GFR above 90 mL/min 1.73 m 2 . Adin et al. (9) studied 184 subjects. They had undergone 2677 enhanced MR examinations. In 103 patients hyperintense dentate nuclei were identified on pre-contrast T1W MR images. Almost all the patients had received only gadopentetate dimeglumine. Quattrocchi et al. (10) found a significant increase in T1 hyperintensity of the dentate nuclei of the cerebellum on nonenhanced scans between the first and the last MRI in the group of patients with a history of at least six enhanced MR examinations, while no difference was seen in those who had between one and five enhanced MR examinations. All 46 patients had received gadodiamide and their glomerular filtration rates were above 60 mL/min 1.73 m 2 . They also showed that no iatrogenic therapeutic intervention was involved in the increase in signal intensity. Progressive increase of T1 signal intensity has also been seen in children (11) .
Animal research
Robert et al. (12) prospectively compared multiple injections of gadoterate meglumine, saline, and gadodiamide in 21 healthy rats (7 per group). Only in the group of rats which had 20 injections of gadodiamide (0.6 mmol/kg) was there an association with progressive and persistent T1 signal hyperintensity in the deep cerebellar nuclei. There was no T1 signal hyperintensity after 20 gadoterate meglumine injections.
Gadolinium in the brain Kanda et al. (13) studied the autopsy findings in five patients who had received a linear gadolinium-based contrast medium and in five patients who had no history of gadolinium-based contrast medium injection. Inductively coupled plasma mass spectroscopy was used to detect the presence of gadolinium. None of the patients had had a GFR below 45 mL/min 1.73 m 2 . Gadolinium was detected in all specimens from patients who had received gadolinium-based contrast medium, but no gadolinium was found in the control group. The highest concentrations were found in the dentate nucleus and globus pallidus. McDonald et al. (14) compared 13 deceased patients who underwent at least four gadodiamide-enhanced brain MR examinations with 10 deceased patients who had never received gadolinium-based contrast medium. Neuronal tissues from the dentate nuclei, pons, globus pallidus, and thalamus from these 23 patients were analyzed with inductively coupled plasma spectrometry. In the patients who had received gadodiamide there were between 0.1 and 58.8 mg gadolinium per gram of tissue in a dose-dependent relationship which correlated with the signal intensity on the nonenhanced T1W MR images. In the control group gadolinium was not found.
In rats Robert et al. (12) found the total gadolinium concentration was 8-52-fold higher in the brain after 20 injections of gadodiamide compared to 20 injections of gadoterate meglumine or saline.
The current techniques used to measure the amount of gadolinium in tissue are much more sensitive than they were in past, so smaller amounts can be detected. However, preparation of brain tissue may remove the water soluble contrast agent, leaving only gadolinium bound to something other than the chelate, and this may lead to underestimation of any accumulation. Also, there is probably a threshold level of gadolinium where hyperintensity can no longer be seen on images, but gadolinium bound to something, unlikely to be a chelate, can still be measured.
Discussion
It is more than 25 years since the first gadolinium-based contrast medium was approved for human use. Why did it take almost 15 years to document the link between some gadolinium-based contrast agents and NSF and a further 8 years to document the link between multiple injections of the same agents and increased signal intensity in the globus pallidus and in the dentate nucleus on unenhanced T1W images? The great increase in the number of MR scanners and the increased number of patients having examinations enhanced with gadolinium based agents is one factor. In the early days enhanced MRI was used very selectively so the number of examinations necessary for these late adverse effects to occur was not reached. Also, these adverse effects are only seen in some patients: NSF only occurs in patients with severely reduced renal function or on dialysis, whereas the increased signal intensity in the brain has been detected only in patients undergoing multiple brain MR examinations. Increased signal intensity in the globus pallidus may occur in patients with severe hepatic disease or on long-term parenteral nutrition (15, 16) . In patients with Rendu-Osler-Weber disease basal ganglia hyperintensity on T1W MRI has also been reported (17) . There have been no reports of basal ganglia hyperintensity in patients who have not received gadolinium-based contrast media, who do not suffer from the other conditions mentioned above and have not had industrial exposure to manganese. It would be appropriate to undertake unenhanced brain MRI in a group of patients undergoing frequent enhanced examinations of the abdomen or women who regularly undergo enhanced MRI of the breasts, who have no symptoms or signs suggestive of brain pathology. We have always believed that extracellular gadolinium-based and iodine-based contrast media do not pass the intact blood-brain barrier.
To date there have been no reports of specific clinical symptoms in patients with signal hyperintensity in the brain on unenhanced T1W images after gadolinium based agents. One possibility is that the brain disease for which they are being evaluated with MRI dominates the symptoms and any adverse effects of gadolinium deposition in the dentate nuclei or globus pallidus are not appreciated. Accumulation of manganese in the same brain areas is associated with Parkinsonism-like symptoms, but the patients with manganese accumulation did not have other brain lesions, unlike the patients with known brain disease who had repeated gadolinium enhanced MR examinations (4) . Gadolinium turned out to be deposited in the capillary endothelium and neural interstitium (14) . This could be an explanation for the lack of symptoms. Studies of the neurotoxicologic effects of gadolinium in the brain are required to evaluate this further.
Further studies are also needed to determine whether T1W brain signal enhancement is related to local dissociation of gadolinium ion from the chelate. Is the gadolinium still bound to the chelate or is it bound to phosphate and calcium as it is in the skin in NSF? It seems most likely that the gadolinium ions are free from the chelate, because it is the less stable gadolinium based agents that are associated with the signal hyperintensity, while the more stable macrocyclic agents are not.
There is enough evidence in the literature to draw some conclusions. It is time to stop the use of any of the less stable agents entirely. This has already happened in Denmark, where less stable agents are no longer registered by the Danish Medicines Agency. The risk of gadolinium accumulation in the brain is present in any examination (e.g. abdomen, prostate, knee) enhanced with a less stable agent. However, current knowledge suggests that it is safe to do multiple enhanced MR examinations with all three macrocyclic agents (gadoterate, gadoteridol, and gadobutrol). Regarding the protein binders, which all are based on a linear chelate, more research is needed.
